New Alliance Capital is the famous VC, which was founded in 2008. The main department of described VC is located in the Shanghai. The venture was found in Asia in China.
We can highlight the next thriving fund investment areas, such as Medical Device, Enterprise. The fund has no exact preference in some founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Sight Diagnostics, Wuhan Zebra Express, ShopEx
This New Alliance Capital works on 18 percentage points less the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 deals per year. Deals in the range of 50 - 100 millions dollars are the general things for fund. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. The increased amount of exits for fund were in 2018. When the investment is from New Alliance Capital the average startup value is 500 millions - 1 billion dollars. Considering the real fund results, this VC is 9 percentage points less often commits exit comparing to other organizations.
The fund was created by Liefeng Qu. We also calculated 3 valuable employees in our database.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the New Alliance Capital, startups are often financed by Sequoia Capital China, Qiming Venture Partners, OurCrowd. The meaningful sponsors for the fund in investment in the same round are Shenzhen Capital Group, Tranquility Capital, Sequoia Capital China. In the next rounds fund is usually obtained by QJY Capital, Tranquility Capital, Steven Esrick.
Related Funds
Funds with similar focus
Fund Name | Location |
Doral Energy-Tech Ventures | Israel, Ramat Gan, Tel Aviv |
Exponentially I Mobility | India, Maharashtra, Mumbai |
Grandbridge | - |
Green Dot Capital | Central, Central Region, Singapore |
HAT Sicaf SpA | Italy, Lombardia, Milano |
IRDI SORIDEC Gestion | - |
Juhe Touzi | Anhui, China, Hefei |
Lendingkart | Ahmedabad, Gujarat, India |
Napier Park Financial Partners | New York, New York, United States |
Navus Ventures | Netherlands, South Holland, The Netherlands |
Newton Press | Japan, Tokyo |
Polish Agency for Enterprise Development | Mazowieckie, Poland, Warszawa |
Rock Central | Detroit, Michigan, United States |
Toyota Industries Corp | Awaji, Hyogo Prefecture, Japan |
U.S. Army Medical Research & Development Command | Louisiana, Maryland, United States |
Valid S.A | Brazil, São Paulo, Sao Paulo |
Weingart Foundation | California, Los Angeles, United States |
Ysios Capital | Barcelona, Catalonia, Spain |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Arnatar Therapeutics | $50M | 09 Apr 2024 | San Diego, California, United States | ||
Elite Technology | $15M | 05 Jan 2024 | Dalian Shi, Liaoning, China | ||
LYNK Pharmaceuticals | $18M | 21 Sep 2023 | Hangzhou, Zhejiang, China | ||
Xbotspace | 08 Aug 2023 | Xuhui, Shanghai, China | |||
Eccogene | $27M | 12 Jun 2023 | Shanghai, China | ||
Lips Semiconductor | $15M | 17 Mar 2023 | Wuxi, Anhui, China | ||
GenScript ProBio | $220M | 18 Jan 2023 | Nanjing, Jiangsu, China | ||
Core Medical Technology | 30 Dec 2022 | Shenzhen, Guangdong, China | |||
NeuroXess | 28 Dec 2022 | Huangpu, Shanghai, China |
– Lynk Pharmaceuticals is a Hangzhou, China-based pharmaceutical R&D company.
– The company completed Series B financing of $50m.
– The round was led by Lilly Asia Ventures (LAV) with participation from New Alliance Capital and Hangzhou HEDA Biological Medicine Venture Capital Partnership (L.L.P.) and its original shareholders Legend Capital and Med-Fine Capital.
– The new investment will be used to conduct Phase I and II clinical trials for multiple programs in the R&D pipeline, expand international business, strengthen international collaborations with companies and support preclinical development of new projects.
– Tavotek Biotherapeutics from Lower Gwynedd, Pennsylvania, has raised over $20M in financing in the preceding two months.
– YuanBio Venture Capital led the A1 finance round followed by Oriza Holdings, Ming BioVentures, and New Alliance Capital.
– Series A2 financing was jointly invested by GF Xinde, CTS Capital, and Lanhu Capital.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Arnatar Therapeutics | $50M | 09 Apr 2024 | San Diego, California, United States | ||
Elite Technology | $15M | 05 Jan 2024 | Dalian Shi, Liaoning, China | ||
LYNK Pharmaceuticals | $18M | 21 Sep 2023 | Hangzhou, Zhejiang, China | ||
Xbotspace | 08 Aug 2023 | Xuhui, Shanghai, China | |||
Eccogene | $27M | 12 Jun 2023 | Shanghai, China | ||
Lips Semiconductor | $15M | 17 Mar 2023 | Wuxi, Anhui, China | ||
GenScript ProBio | $220M | 18 Jan 2023 | Nanjing, Jiangsu, China | ||
Core Medical Technology | 30 Dec 2022 | Shenzhen, Guangdong, China | |||
NeuroXess | 28 Dec 2022 | Huangpu, Shanghai, China |